G-Pen + Lilly Glucagon
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Insulin Hypoglycemia
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Trial Timeline
Jan 23, 2018 → May 3, 2018
NCT ID
NCT03439072About G-Pen + Lilly Glucagon
G-Pen + Lilly Glucagon is a phase 3 stage product being developed by Xeris Pharmaceuticals for Insulin Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03439072. Target conditions include Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia.
What happened to similar drugs?
8 of 20 similar drugs in Insulin Hypoglycemia were approved
Approved (8) Terminated (1) Active (12)
✅Glucovance (metformin HCl/glyburide) + or Metformin HCl alone + or Glyburide alone.Bristol Myers SquibbApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03439072 | Phase 3 | Completed |
Competing Products
20 competing products in Insulin Hypoglycemia